Where is the live CopyMark page for USPTO serial 75425166?

The live record is at https://getcopymark.com/trademark/75425166. Use https://getcopymark.com/trademark/{serialNumber} for any 8-digit USPTO serial.

Who owns NANOTHERAPEUTICS?

According to the public USPTO record for serial number 75425166, the listed owner(s) include: NanoSystems L.L.C., NanoSystems L.L.C..

What is USPTO serial number 75425166?

Serial number 75425166 is the USPTO application identifier for the mark NANOTHERAPEUTICS. It is used to track examination, publication, and registration of this trademark.

What is the current status of NANOTHERAPEUTICS?

NANOTHERAPEUTICS (75425166) currently shows USPTO status code 614 on the public record. This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Which trademark classes cover NANOTHERAPEUTICS?

The public record lists International Classes: 005. Each class corresponds to categories of goods or services identified in the application or registration.

Trademark: NANOTHERAPEUTICS Serial# 75425166 | status 614; last event PETD | Trademark Info & Attorney Guidance

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with NANOTHERAPEUTICS?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner

Monitor this mark, or talk with CopyMark about this registration.

Trademark Monitoring

(312) 319-4460

Not the owner?

File a new U.S. trademark application, or speak with our attorneys.

Start a new application

(312) 319-4460

Owner

NanoSystems L.L.C.
King of Prussia, PA
Other trademarks owned by NanoSystems L.L.C.
NanoSystems L.L.C.
King of Prussia, PA
Other trademarks owned by NanoSystems L.L.C.

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

KATHLEEN L. MAHER

KATHLEEN L MAHER ELAN PHARMACEUTICAL RESEARCHASSISTANT PATENT COUNSEL1300 GOULD DRGAINESVILLE, GA 30504-3947

Goods and services

Class	Description	Status	First use
005	Pharmaceutical preparations, namely, adjuvant preparations sold as a component of a full line of pharmaceuticals, and ingredients and components thereof, namely, ultra-small particle formulations	ACTIVE	—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Date	Code	Event	What it means
Jan 31, 2002	PETD	PETITION TO REVIVE-DENIED	—
Jun 18, 2001	PINM	INCOMPLETE PETITION NOTICE MAILED	—
Apr 20, 2001	ABN6	ABANDONMENT - NO USE STATEMENT FILED	The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Oct 19, 2000	PETR	PETITION TO REVIVE-RECEIVED	—
May 9, 2000	EX2G	SOU EXTENSION 2 GRANTED	—
Apr 13, 2000	EXT2	SOU EXTENSION 2 FILED	—
Nov 17, 1999	EX1G	SOU EXTENSION 1 GRANTED	—
Oct 12, 1999	EXT1	SOU EXTENSION 1 FILED	—
Apr 13, 1999	NOAM	NOA MAILED - SOU REQUIRED FROM APPLICANT	A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Jan 19, 1999	PUBO	PUBLISHED FOR OPPOSITION	Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Dec 18, 1998	NPUB	NOTICE OF PUBLICATION	—
Sep 28, 1998	CNSA	APPROVED FOR PUB - PRINCIPAL REGISTER	—
Sep 21, 1998	DOCK	ASSIGNED TO EXAMINER	—
Sep 13, 1998	DOCK	ASSIGNED TO EXAMINER	—

NANOTHERAPEUTICS